Trial Profile
A Randomized Evaluation of Vinorelbine Versus Gemcitabine for Mobilization of Peripheral Stem Cells in Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Granulocyte colony-stimulating factors; Vinorelbine
- Indications Amyloidosis; Multiple myeloma
- Focus Therapeutic Use
- Acronyms ViGeM
- 31 Mar 2018 Status changed from active, no longer recruiting to completed.
- 13 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2016 New trial record